Mesoblast MESO
NASDAQ MESO
$17.32 +0.18 (+1.05%)
At close: Sep 4, 2026 · 4:00 PM EDT

Mesoblast (MESO) Change in Receivables (2014 - 2024)

Mesoblast (MESO) posted Change in Receivables of $9000.0 for Q1 2023, up 100.71% sequentially from -$1.3 million in Q4 2022, and down 97.81% YoY from $411000.0 in Q1 2022.

Analysis

Mesoblast (MESO) Change in Receivables (2014 - 2024) Analysis & Trends

Mesoblast has reported Change in Receivables for 8 years, with the latest figure at $9000.0 in Q1 2023.

  • Quarterly Change in Receivables fell 97.81% year-over-year to $9000.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $499000.0 (up 132.79% YoY) and the FY2022 annual result came in at $140000.0, up 108.05% from the prior year.
  • Change in Receivables rose to $9000.0 in Q1 2023 per MESO's latest filing, from -$1.3 million in the prior quarter.
  • Over five years, Change in Receivables peaked at $14.8 million in Q4 2019 and troughed at -$15.4 million in Q3 2019.
  • A 5-year average of -$97294.1 and a median of $9000.0 in 2023 frame the typical range for Change in Receivables.
  • The sharpest annual moves came in 2021 and 2022: Change in Receivables jumped 551.56% in 2021, then slumped 197.64% in 2022.
  • Over 5 years, Change in Receivables stood at $14.8 million in 2019, then plunged by 105.81% to -$858000.0 in 2020, then jumped by 50.58% to -$424000.0 in 2021, then plunged by 197.64% to -$1.3 million in 2022, then soared by 100.71% to $9000.0 in 2023.
  • According to Business Quant data, Change in Receivables over the past three periods registered $9000.0, -$1.3 million, and $519000.0 for Q1 2023, Q4 2022, and Q3 2022 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 140.20 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 838.50 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -53.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 117.58 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 31.60 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 37.16 Mn
10 Mesoblast 2.24 Bn 2.14 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2024 -15.47 Mn
Jun 30, 2023 -118,000.00
Mar 31, 2023 9,000.00
Dec 31, 2022 -1.26 Mn
Sep 30, 2022 519,000.00
Jun 30, 2022 1.23 Mn
Mar 31, 2022 411,000.00
Dec 31, 2021 -424,000.00
Sep 30, 2021 -1.08 Mn
Jun 30, 2021 -429,000.00
Mar 31, 2021 417,000.00
Dec 31, 2020 -858,000.00
Sep 30, 2020 -869,000.00
Mar 31, 2020 -556,000.00
Dec 31, 2019 -620,000.00
Sep 30, 2019 -15.38 Mn
Mar 31, 2019 358,000.00
Dec 31, 2018 20.56 Mn
Sep 30, 2018 -19.62 Mn
Jun 30, 2018 597,000.00